Opioid use disorders are a global public health concern with less-than-optimal treatment outcomes. In the past year over 15 million Americans have misused opioids. Many of these incidents have been characterized by unintentional poisoning deaths involving synthetic opioids such as fentanyl and carfentanil. The traditional mindset for treating opioid disorders has involved a pharmacodynamic strategy, modulating or disrupting the effects of the drug at sites of action in the body. Unfortunately, this has not yielded broadly effective medications. In view of these limitations, we have investigated a pharmacokinetic strategy. Our approach involves the use of antibodies that target the drug itself to keep the drug below its minimally effective concentration at its sites of action. In this context we will discuss our research program for targeting these synthetic opioids.

Pharmacokinetic strategy for treatment of opioid overdose and addiction

Fall 2022 abstracts, posters, and presentations will launch in mid-September.

ACS Fall 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.